

Special Issue

Cancer Heterogeneity: Biomarkers and Targeted Therapies

Message from the Guest Editors

Cancer cannot be understood as a single disease but rather a collection of distinct tumor subtypes. Tumor cells are extremely plastic and dynamic, and the diversity of phenotypes observed in tumors reflects the array of cell types present in the tumor. The extended use of cutting-edge technologies such as single-cell and spatially resolved transcriptomics provides powerful tools to unravel molecular and cellular features of tumor heterogeneity, with the great potential of being translated into new and reliable biomarkers, and novel targeted therapies. In this Special Issue, we invite reviews and original research manuscripts that examine how cancer heterogeneity can be exploited to identify new biomarkers and molecular drivers responsible for tumor maintenance, circumvent drug resistance, and/or develop effective targeted therapies in the path of getting closer the personalized medicine to cancer patients.

- tumor heterogeneity
- biomarkers
- targeted therapies
- personalized medicine

Guest Editors

Dr. Verónica Rodilla

Josep Carreras Leukaemia Research Institute, 08916 Badalona, Spain

Dr. Cristina Guardia

Josep Carreras Leukaemia Research Institute, 08916 Badalona, Spain

Deadline for manuscript submissions

closed (31 May 2023)



Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



mdpi.com/si/121027

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)





Biomedicines

an Open Access Journal
by MDPI

Impact Factor 3.9
CiteScore 7.8
Indexed in PubMed



[mdpi.com/journal/
biomedicines](https://mdpi.com/journal/biomedicines)



About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA

2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21 days after submission; acceptance to publication is undertaken in 2.8 days (median values for papers published in this journal in the second half of 2025).